CJC
Modified Growth Hormone Releasing Factor (1-29), proposed to provide more stable GH release when combined with GHRPs (no primary study found). Also known as Mod GRF 1-29.
2 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
CJC-1295 (no DAC) is a compound studied only in animals and lab experiments so far. Modified Growth Hormone Releasing Factor (1-29), proposed to provide more stable GH release when combined with GHRPs (no primary study found).
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published studies of Mod GRF(1-29)/CJC-1295 no DAC found detailsNo published studies of Mod GRF(1-29)/CJC-1295 no DAC found. CJC-1295 with DAC: 30 or 60 µg/kg s.c. single/weekly doses in healthy adults. Sermorelin: 1 µg/kg i.v. as a diagnostic GH stimulation test in children.Community-reportedCommunity-reported: 100–200 mcg, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is expected to prompt the pituitary gland to release growth hormone, based on similar compounds; it has not been studied directly. Proposed mechanism, inferred from related GHRH analogues (no published studies of this compound were found): a GHRH-receptor agonist expected to stimulate pituitary GH release. The related GHRH analogue sermorelin (GRF 1-29) stimulates GH secretion from the anterior pituitary (Prakash 1999).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedIn user communities, CJC-1295 (no DAC) is typically run at 100–200 mcg (subcutaneous injection). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| CJC-1295 (no DAC) | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| CJC-1295 (with DAC) | 6-8 days | Subcutaneous injection | Phase 1 / early human |
| GHRP-2 | No published PK data found | Subcutaneous injection | Phase 1 / early human |
| GHRP-6 | No published PK data found | Subcutaneous injection | Phase 1 / early human |
| Hexarelin | No published PK data found | Subcutaneous injection | Phase 1 / early human |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Growth Hormone category. View All Growth Hormone Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.